Importantly, increased activity of Plk1 is closely linked to malignancy, and Plk1 inhibition sensitizes cancer cells to DNA damage treatment (Strebhardt, 2010; Sur et al., 2009; Taylor and Peters, 2008). Here, PLK1 is linked to cancer.